Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Eating More Tomatoes Lowers Prostate Cancer (PCa) Risk

Eating More Tomatoes Lowers Prostate Cancer (PCa) Risk

Consuming ten portions of tomatoes a week can lower the risk of prostate cancer.

Aspirin May Lower Non-Metastatic Prostate Cancer Mortality

Aspirin May Lower Non-Metastatic Prostate Cancer Mortality

Significant association observed for high-risk prostate cancers with no difference according to daily dose.

Vitamin D May Suppress Prostate Tissue Inflammation

Vitamin D May Suppress Prostate Tissue Inflammation

Vitamin D may be able to suppress inflammation in prostate tissue by boosting expression of the GDF-15 gene.